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Cytomegaloviruses (CMV) can have a significant impact on the prognosis of immunocom-
promised patients. Unlike in the transplantation and AIDS fields, only a few studies on CMV
infections have been published in the field of autoimmunity. In this study, we examined the
clinical outcomes of CMV infections in patients with autoimmune diseases at a single tertiary
medical institution.
Methods
A retrospective study was performed to identify the mortality risk factors associated with
CMV infections in patients with autoimmune diseases. We reviewed the medical records of
patients with autoimmune diseases who were diagnosed with CMV infections using real-
time quantitative polymerase chain reaction between December 2005 and March 2016.
Clinical and laboratory parameters as well as treatment outcomes were analyzed.
Results
Seventy-three CMV infected patients were separated into survivors and non-survivors.
Non-survivors had significantly higher median CMV-DNA copy numbers than survivors
(95,500 vs 6,700 copies/mL, p = 0.005) and demonstrated significantly more frequent inci-
dents of CMV pneumonitis (69.2 vs 36.2%, p = 0.007). After adjusting for multiple confound-
ing covariates, the log CMV-DNA copies/mL (hazard ratio, 1.48; 95% confidence interval,
1.14–1.92; p = 0.003) and the presence of concurrent infections (hazard ratio, 22.00; 95%
confidence interval, 2.75–175.97, p = 0.004) were identified as independent mortality risk
factors. Furthermore, patients with high CMV copy numbers (> 60,000 copies/mL) had
higher in-hospital mortality than those with low CMV copy numbers (p < 0.05).
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Conclusions
CMV-DNA copy numbers and concurrent infections are predictors of in-hospital mortality in
CMV-infected patients with autoimmune diseases. Therefore, serial measurements of
CMV-DNA copy numbers and close observation for signs of other infections are recom-
mended for patients with autoimmune diseases who have concurrent CMV infection.
Introduction
Cytomegalovirus (CMV) is a common virus that can adversely affect the prognosis of immu-
nocompromised patients, especially those with AIDS and solid organ or hematopoietic stem
cell transplantation [1]. CMV is transmitted via multiple routes, including direct contact with
infected saliva or breast milk, sexual transmission, vertical transmission, and blood transfu-
sions. Latent CMV infection may remain dormant throughout the patient’s lifetime [2]. How-
ever, when the host immune system deteriorates, the latent virus may reactivate with or
without symptoms [3]. CMV is known to damage various organs, including the lung, liver,
gastrointestinal tract, bone marrow, and retina.
Although many researchers have investigated the clinical implications of CMV infections
in patients that undergo organ transplantation and in those with AIDS [4–6], we still lack an
understanding of how CMV infection may affect the outcomes in autoimmune disorders [7].
Patients with autoimmune diseases are particularly susceptible to CMV infection because of
their disrupted immune system and frequent immunosuppressive treatments. Furthermore,
novel immunosuppressive drugs such as anti-tumor necrosis factor antibodies, Janus kinase
inhibitors, and anti-CD20 antibodies increase their risk of infection [8, 9]. Therefore, ques-
tions continue to grow regarding the clinical impact of CMV infection in patients with auto-
immune diseases.
CMV quantitative real-time polymerase chain reaction (PCR) is the preferred method for
the diagnosis of CMV infection [10]. It is a very sensitive assay capable of detecting and quanti-
fying even a small amount of viral nucleic acids [11]. However, when CMV PCR tests are posi-
tive, the technique is unable to determine whether the infection is latent or has developed into
an active end-organ disease. Furthermore, we still lack clear guidelines in the management of
CMV infections in patients with autoimmune diseases. In this retrospective observational
study, we evaluated the association between CMV infections and survival outcomes in hospi-
talized patients with autoimmune diseases and identified the risk factors for in-hospital mor-
tality in this population.
Materials and methods
Study design and patient selection
This is a retrospective observational study over a 10-year period at a single tertiary medical
institution to identify the mortality risk factors associated with CMV infections in patients
with autoimmune diseases. We reviewed the medical records of hospitalized patients with
autoimmune diseases who were evaluated for CMV infections because of clinical suspicion at
the Yonsei University Severance Hospital (Seoul, South Korea) between December 1, 2005,
and March 31, 2016. Patients aged 18–85 were included in our study. Patients were excluded if
they had also been diagnosed with cancer or HIV infection and/or if they had undergone
organ or hematopoietic stem cell transplantation. This study was approved by the Institutional
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Review Board at Severance Hospital (IRB approval number 4-2016-1154) and was conducted
in accordance with the principles set forth in the Declaration of Helsinki. The requirement to
obtain informed consent was waived because of the retrospective nature of the study.
Data collection
We collected the following data for each patient: age, sex, disease duration, white blood cell
and differential counts, hemoglobin level, platelet count, total protein and albumin levels,
erythrocyte sedimentation rate, C-reactive protein level, CMV-DNA copy numbers, clinical
manifestations, comorbid conditions, medications, clinical outcomes, ventilator use, and pres-
ence of other infections. When CMV-DNA copy numbers were measured more than once,
the highest copy numbers were used for analysis. Laboratory data collected on the day with
the highest recorded CMV-DNA copy numbers were used. The mean daily steroid dose was
calculated using the accumulated steroid doses within 30 days from the day the highest
CMV-DNA copy number was reported. All steroid doses were converted to equivalent doses
of methylprednisolone.
Definitions
CMV infection was defined as the detection of CMV PCR positivity in the blood or body flu-
ids. CMV disease was defined as a condition in which the organ involvement of CMV infec-
tion was confirmed. Asymptomatic CMV infection was defined as a condition in which the
patient showed CMV PCR positivity with no symptoms or organ involvement.
Quantitative PCR for CMV
To perform quantitative real-time PCR for CMV, DNA was extracted from whole blood using
a QIAamp DSP DNA Mini Kit (Qiagen, Germany) and QIAcube (Qiagen, Germany) in accor-
dance with the manufacturer’s instructions. Real-time PCR for CMV-DNA was performed
using the LightCycler 480 (Roche Diagnostics, Germany) and Bio-Core CMV Quantification
real-time PCR kit (Bio-Core, Korea). For the standardization of the results, the World Health
Organization International Standard for human CMV for nucleic acid amplification tech-
niques was used. The data were reported as copies/mL.
Statistical analysis
The Statistical Analysis System (SAS) version 9.4 software (SAS, Cary, NC, USA) was used for
all data analyses. Non-normally distributed data are presented as medians (interquartile
ranges) and categorical variables are expressed as counts (%). For continuous variables, group
comparisons were performed using the Mann-Whitney U test. Categorical data were com-
pared using the chi-squared or Fisher’s exact tests. Risk factors for in-hospital mortality in
patients with autoimmune diseases and concurrent CMV infections were identified using uni-
variate and multivariate logistic regression analyses, with the hazard ratios (HRs) listed along
with 95% confidence intervals (CIs). For multivariate analysis, factors that were statistically
significant in the univariate logistic model were used. The maximal cut-off value for the
CMV-DNA copy number to predict in-hospital mortality was calculated using area under the
receiver operating characteristic (ROC) curve analyses and the survival rates of patients were
compared using the Kaplan-Meier method. In all statistical analyses, a two-tailed p-value
<0.05 was considered statistically significant.
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Results
Patient baseline characteristics
We identified 73 CMV PCR positive and 123 CMV PCR negative autoimmune patients. Mor-
tality rate was higher in the CMV PCR positive patients than in the CMV PCR negative
patients (35.6% vs 11.4%, p< 0.001, S1 Table). Among the 73 CMV PCR positive patients
enrolled in the further analysis, the median age was 58 years; 25 were male and 48 were female;
the median disease duration was 3 years (range, 1–10). Autoimmune diseases consisted of 28
cases (38.4%) of systemic lupus erythematosus (SLE), 18 cases (24.6%) of rheumatoid arthritis
(RA), 12 cases (16.4%) of vasculitis, 9 cases (12.3%) of inflammatory myositis, 3 cases (4.1%) of
Behc¸et disease, and 3 cases (4.1%) of adult-onset Still disease. Non-survivors had significantly
higher mean CMV-DNA copy numbers than survivors (p = 0.005). In addition, non-survivors
had significantly lower total protein (p = 0.025) and albumin (p = 0.007) levels than survivors
(Table 1).
Clinical features of CMV infections
CMV end-organ diseases consisted of pneumonitis, retinitis, enteritis, and hepatitis; 73.1% of
non-survivors and 44.8% of survivors had CMV end-organ diseases while 26.9% of non-survi-
vors and 55.3% of survivors had asymptomatic CMV infections. Survivors had fewer cases of
CMV pneumonitis (p = 0.007) and more cases of asymptomatic CMV infection (p = 0.020)
than non-survivors. Non-survivors required mechanical ventilation more frequently than did
survivors (p< 0.001). The frequency of ganciclovir treatment was comparable in the two
groups (Table 2). We further evaluated whether a higher mortality rate is associated with cer-
tain autoimmune diseases. The majority of patients were diagnosed as having SLE, RA, vascu-
litis, and myositis (Table 2). There was no difference in mortality rate in specific autoimmune
diseases.
Table 1. Baseline characteristics according to disease outcome in CMV PCR positive patients.
Non-survivors (n = 26) Survivors (n = 47) p-value
Age (years) 64.0 (49.0–72.0) 58.0 (43.2–66.0) 0.271
Female sex, n (%) 17 (65.3) 31 (65.9) 0.960
CMV-DNA (copies/mL) 95,500.0 (5150.0–315,000.0) 6700.0 (3995.0–40,950.0) 0.005
WBC count (/μL) 8620.0 (5490.0–12,480.0) 8270.0 (4940.0–14,020.0) 0.670
Neutrophil count (/μL) 8045.0 (4860.0–11,210.0) 7210.0 (4090.0–12,330.0) 0.397
Lymphocyte count (/μL) 415.0 (260.0–620.0) 420.0 (190.0–890.0) 0.895
Hemoglobin (g/dL) 10.0 (9.0–10.0) 10.0 (8.0–11.0) 0.683
Platelet count (/103 μL) 129.0 (77.0–242.0) 198.0 (119.0–322.0) 0.106
BUN (mg/dL) 29.0 (18.0–47.0) 21.0 (11.0–34.0) 0.040
Cr (mg/dL) 1.0 (1.0–2.0) 1.0 (1.0–1.0) 0.444
Total protein (mg/dL) 5.0 (4.0–5.0) 5.0 (5.0–6.0) 0.025
Albumin (mg/dL) 2.0 (2.0–3.0) 3.0 (2.0–3.0) 0.007
ESR (mm/hr) 27.0 (6.0–92.0) 53.0 (17.0–83.0) 0.284
CRP (mg/L) 54.0 (31.0–97.0) 52.0 (5.0–114.0) 0.565
Values are expressed as medians (Q1–Q3) or counts (%). P-values are based on the Mann-Whitney U test, chi-squared test, or Fisher’s exact test. BUN,
blood urea nitrogen; CMV, cytomegalovirus; Cr, creatinine; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell.
https://doi.org/10.1371/journal.pone.0181590.t001
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Immunosuppressive treatments
There were no significant differences in the types of drugs used by the survivors and non-sur-
vivors (Table 3). The median steroid dose was not significantly different in the two groups
(32.07 vs 24 mg/day). The proportion of patients taking cyclophosphamide or other immuno-
suppressants was also comparable in the two groups.
Table 2. Clinical features of cytomegalovirus (CMV) infections.
Non-survivors (n = 26) Survivors (n = 47) p-value
Organ involvement
CMV pneumonitis 18 (69.2) 17 (36.2) 0.007
CMV colitis 0 (0.0) 2 (4.3) 0.535
CMV retinitis 0 (0.0) 2 (4.3) 0.535
CMV hepatitis 1 (3.9) 0 (0.0) 0.356
Asymptomatic CMV infection 7 (26.9) 26 (55.3) 0.020
Treatment
Use of ganciclovir 15 (57.7) 20 (42.6) 0.215
Use of ventilator care 21 (80.8) 2 (4.3) <0.001
Type of autoimmune diseases 0.435
Systemic lupus erythematosus 7 (26.9) 21 (44.7)
Rheumatoid arthritis 7 (26.9) 11 (23.4)
Vasculitis 5 (19.2) 7 (14.9)
Inflammatory myositis 5 (19.2) 4 (8.5)
Adult-onset Still disease 2 (7.7) 1 (2.1)
Behc¸et disease 0 (0.0) 3 (6.4)
Values are expressed as counts (%). P-values were calculated with the chi-squared or Fisher’s exact tests.
https://doi.org/10.1371/journal.pone.0181590.t002
Table 3. Medications administered to patients in the survivor and non-survivor groups.
Non-survivors (n = 26) Survivors (n = 47) p-value
Steroids
Steroid dose (mg/day) 32.1 (17.3–49.5) 24.0 (8.0–75.9) 0.256
Steroid only 5 (19.2) 16 (34.0) 0.181
Steroid plus cyclophosphamide 4 (15.4) 5 (10.6) 0.712
Steroid plus other immunosuppressants 17 (65.4) 26 (55.3) 0.403
Immunosuppressants
Cyclophosphamide 4 (15.4) 5 (10.6) 0.712
Methotrexate 4 (15.4) 9 (19.2) 0.760
Leflunomide 1 (3.9) 0 (0.0) 0.356
Azathioprine 3 (11.5) 9 (19.2) 0.519
Mycophenolate mofetil 3 (11.5) 4 (8.5) 0.694
Calcineurin inhibitors 1 (3.9) 2 (4.3) 0.999
Rituximab 2 (7.7) 1 (2.1) 0.287
Tumor necrosis factor inhibitors 1 (3.9) 0 (0.0) 0.356
None 2 (7.7) 1 (2.1) 0.287
Values are expressed as medians (Q1–Q3) or counts (%). P-values are based on the Mann-Whitney U test, chi-squared test, or Fisher’s exact test. Values
are expressed as counts (%). P-values were calculated with the chi-squared or Fisher’s exact tests.
https://doi.org/10.1371/journal.pone.0181590.t003
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Evaluation of concurrent infections
There was no significant difference in the number of patients infected by each bacterial strain
identified in the two groups (Table 4). However, non-survivors were infected more frequently
by multiple microbes than survivors (57.7% vs 27.7%, p = 0.012). Pneumocystis jiroveci infec-
tion was twice as common in non-survivors as in survivors, although the difference was not
statistically significant.
Mortality risk factors
We utilized univariate analyses to determine whether any clinical features of the patients
increased the mortality risk. To calculate the validity and significance of the risk factors, we
performed a logistic regression analysis. The log CMV-DNA copy number (univariate HR,
1.479; 95% CI, 1.140–1.918; p = 0.003, multiple 1 HR, 1.415; 95% CI, 1.027–1.950; p = 0.034,
multiple 2 HR, 1.409; 95% CI, 1.016–1.954; p = 0.040) and the presence of concurrent infec-
tions (univariate HR, 22.000; 95% CI, 2.750–175.971; p = 0.004, multiple 1 HR, 16231; 95% CI,
1.846–142.681; p = 0.012, multiple 2 HR, 18.425; 95% CI, 2.109–161.006; p = 0.008) were iden-
tified as significant mortality risk factors (Table 5).
Area under the ROC curve analysis revealed that CMV-DNA copy number> 60,000 cop-
ies/mL was the best cut-off for predicting in-hospital mortality in patients with CMV infection.
Kaplan-Meier analysis with the log-rank test showed that the in-hospital mortality rate was
higher in patients with CMV-DNA copy numbers greater than 60,000 copies/mL (p< 0.05)
(Fig 1a). We further analyzed patients’ survival according to ganciclovir treatment. Because
CMV PCR test was performed multiple times in the same patient, the highest copy number
was used for the survival analysis. The highest CMV-DNA copy number was observed before
ganciclovir treatment in all patients, except in one patient, who had highest copy number after
ganciclovir treatment. Although the survival probability of patients with ganciclovir treatment
was higher than that of patients without ganciclovir treatment in the high-titer CMV-DNA
patient group, the survival benefit of ganciclovir was insignificant in both the high- and the
low-titer CMV groups (Fig 1b).
Table 4. Comparison of microbes in the survivor and non-survivor groups.
Non-survivors (n = 26) Survivors (n = 47) p-value
Type of infection
Single organism 10 (38.5) 12 (25.5) 0.249
Multiple organisms 15 (57.7) 13 (27.7) 0.012
No organism 1 (3.8) 22 (46.8) <0.001
Identified pathogens
Acinetobacter baumannii 7 (26.9) 5 (10.6) 0.101
Enterococcus species 5 (19.2) 3 (6.4) 0.124
Escherichia coli 0 (0) 3 (6.4) 0.548
Klebsiella pneumoniae 0 (0) 3 (6.4) 0.548
Pseudomonas aeruginosa 3 (11.5) 2 (4.3) 0.340
Staphylococcus aureus 1 (3.8) 1 (2.1) 1.000
Clostridium difficile 1 (3.8) 3 (6.4) 1.000
Pneumocystis jiroveci 9 (34.6) 8 (17.0) 0.089
Aspergillus species 6 (23.1) 9 (19.1) 0.696
Values are expressed as counts (%). P-values were calculated with the chi-squared or Fisher’s exact tests.
https://doi.org/10.1371/journal.pone.0181590.t004
CMV infection in autoimmune diseases
PLOS ONE | https://doi.org/10.1371/journal.pone.0181590 July 25, 2017 6 / 12
Effect of ganciclovir treatment on the CMV-DNA copy number
Thirty-five (48%) patients received ganciclovir, which included 8 patients who had missing
CMV-DNA copy number follow-up data. In the remaining 27 patients, ganciclovir treatment
reduced the CMV-DNA copy number in both the survivor and non-survivor groups (Table 6).
However, the negative conversion rate was lower in the non-survivor group than in the survi-
vor group (p = 0.023).
Discussion
Latent CMV infection may persist without causing any harm in healthy individuals [1]. Even
though it has been widely accepted that CMV infection may lead to severe or even fatal ill-
nesses in immunocompromised conditions, such as HIV infection, hematologic malignancies,
organ transplantation, or immunosuppressive therapy [3], only a few studies have investigated
the association between CMV infection and patient survival in autoimmune disorders [12–
14]. In our study involving a 10-year period in a single tertiary medical institute, we demon-
strated that the mortality rate was significantly higher in patients with autoimmune diseases
diagnosed with CMV infections. Furthermore, the incidence of CMV pneumonitis was signifi-
cantly higher in non-survivors than in survivors. Our data do not prove that CMV infection is
the direct cause of mortality because 26.9% of non-survivors had asymptomatic CMV infec-
tion. Even for patients with CMV end-organ diseases, it is difficult to identify the primary
cause of death in cases of CMV infection in the presence of autoimmune diseases because the
patients often have multiple medical conditions, including systemic inflammation due to auto-
immune diseases, and other concurrent infections. However, it is important to understand the
risk factors for mortality when patients with autoimmune diseases are infected with CMV.
CMV PCR is a widely available rapid and sensitive technique for CMV detection [15].
CMV-DNA copy number is a useful marker to predict the progression of CMV infection [16].
It has been used to determine the response to treatment and to identify patients at risk of
CMV disease after transplantation for preemptive therapy [15, 17]. In the present study, we
found that the CMV-DNA copy numbers were significantly higher in non-survivors than in
survivors (Table 1). Consistent with this finding, the Kaplan-Meier curves demonstrated a
lower survival rate in patients with CMV-DNA copy numbers greater than 60,000 copies/mL
(Fig 1). Univariate and multivariate logistic regression analyses for in-hospital mortality
revealed that log CMV-DNA copy number was a significant independent mortality risk factor.
Table 5. Survival outcomes associated with mortality risk factor among cytomegalovirus (CMV)-infected patients.
Univariate HR (95% CI) p-value Multivariate 1 HR (95% CI) p-value Multivariate 2 HR (95% CI) p-value
Age 1.012 (0.981–1.044) 0.441 0.998 (0.957–1.041) 0.924 1.004 (0.964–1.045) 0.844
Female sex 1.026 (0.374–2.812) 0.961 1.082 (0.284–4.123) 0.908 1.037 (0.274–3.921) 0.958
Other infections 22.000 (2.750–175.971) 0.004 16.231 (1.846–142.681) 0.012 18.425 (2.109–161.006) 0.008
Log CMV PCR 1.479 (1.140–1.918) 0.003 1.415 (1.027–1.950) 0.034 1.409 (1.016–1.954) 0.040
Ganciclovir 0.543 (0.206–1.432) 0.217 0.864 (0.226–3.309) 0.864 0.815 (0.221–3.008) 0.759
Pulsed MPSL 0.948 (0.337–2.667) 0.920 1.331 (0.259–6.847) 0.732 1.548 (0.287–8.334) 0.611
Oral steroid 1.000 (0.999–1.001) 0.813 0.993 (0.982–1.004) 0.199 0.994 (0.983–1.005) 0.271
Log WBC count 1.384 (0.706–2.713) 0.345 1.342 (0.620–2.904) 0.455
Log Lymphocyte 1.153 (0.819–1.623) 0.414 1.319 (0.673–2.588) 0.420
Values are expressed as HR (95% CI). P-values were calculated using logistic regression models. CI, confidence interval; HR, hazard ratio; MPSL,
methylprednisolone; WBC, white blood cell.
https://doi.org/10.1371/journal.pone.0181590.t005
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Interestingly, however, Takizawa et al. [14] reported that CMV pp65 antigenemia did not
cause significant increases in mortality risk among 151 Japanese patients with autoimmune
diseases among whom 50% had SLE. Rather, other factors such as lymphopenia, infectious
complications, and clinical symptoms were significant risk factors. Similar to our findings,
Fig 1. Kaplan-Meier survival analysis of patients with autoimmune disease and CMV infection
according to CMV-DNA copy number. (a) Survival analysis according to CMV titer. (b) Subgroup survival
analysis according to ganciclovir (Gan) treatment. Cut-off value 60,000 copies/mL, log-rank test p < 0.001.
https://doi.org/10.1371/journal.pone.0181590.g001
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Tsai et al. [18] reported that CMV pp65 antigenemia or lymphopenia predicted mortality or
morbidity in 54 Chinese patients with autoimmune diseases, among whom 70% had SLE.
Because CMV pp65 antigenemia detection is labor-intensive and is limited by the need for
immediate processing and subjective bias in interpretation, most laboratories are now using
quantitative real-time PCR based technologies [19]. Our study differs from previous studies,
given that we evaluated the association between in-hospital mortality and high CMV-DNA
copy numbers, which is more relevant to current practice pattern. Another study by Dodt
et al. [4] demonstrated that lymphopenia and leukopenia significantly increased the mortality
rate of patients with AIDS. In our study, however, neither lymphopenia nor leukopenia
appeared to be a significant risk factor. This discrepancy might be due to differences in the
underlying diseases. In our study, total protein and albumin levels were lower in the non-sur-
vivors than in the survivors. Interestingly, Borthakur et al. [20] also reported that low serum
albumin was associated with CMV reactivation in patients with leukemia who were treated
with anti-CD52 antibody. Low serum albumin could be associated with susceptibility to CMV
infection due to low nutritional or general immune status.
Current CMV anti-viral treatment recommendations are based on the clinical manifesta-
tions of the infection. Since potent immunosuppressive treatment can trigger CMV reactiva-
tion, it is clinically challenging to distinguish CMV infection from CMV disease in patients
with autoimmune diseases. To make the situation more complex, there can be additional
opportunistic infections or hospital-acquired bacterial infections in febrile patients with auto-
immune diseases who receive long-term immunosuppressive therapy. Pre-emptive anti-viral
treatment has proven effective in lowering the incidence and mortality rates of CMV disease
in patients that undergo transplantation [5, 6, 10]. Ganciclovir treatment did not significantly
improve survival outcomes in patients with autoimmune diseases in our study (Table 5), but
it was effective in reducing CMV-DNA titer in both the survivor and non-survivor groups
(Table 6). Therefore, CMV may not be a major factor associated with mortality of autoim-
mune patients. It is possible that the elevation of CMV-DNA copy numbers occurred second-
ary to severe immune suppression in our patients. As patients with autoimmune diseases have
dysregulated immune systems, which often require frequent immunosuppressive treatments,
they are susceptible to infection. Given that 96.2% of non-survivors had other bacterial or
fungal infections while only 53.2% of survivors had other infections (Table 4), concurrent
infections appeared to have contributed to mortality in our patients. Univariate analysis con-
sistently indicated that concurrent bacterial or fungal infections had a HR of 22 (Table 5;
p = 0.004), which is greater than the HR for CMV-DNA copy number (HR = 1.479,
p = 0.003).
There are factors that we could not control in our study in demonstrating the treatment
benefit on survival such as (i) small sample size for subgroup analysis, (ii) suboptimal CMV
treatment for the non-survival group, and (iii) heterogeneity of concurrent infection. In fact,
Table 6. Effect of ganciclovir treatment on the CMV-DNA copy number.
Survivor (n = 15) Non-survivor (n = 12) p-value
CMV-DNA copy number before ganciclovir treatment 39,750.0 (13,300.0–88,875.0) 186,500.0 (8375.0–551,500.0) 0.525
CMV-DNA copy number after ganciclovir treatment 0.0 (0.0–0.0)* 832.5 (0.0–5652.5)** 0.013
Ganciclovir treatment duration (days) 20.0 (10.3–21.5) 13.5 (12.5–16.0) 0.180
Negative conversion rate (%) 14 (93.3) 6 (50.0) 0.023
*p = 0.001, CMV-DNA copy number before and after ganciclovir treatment in survivors.
**p = 0.005, CMV-DNA copy number before and after ganciclovir treatment in non-survivors.
https://doi.org/10.1371/journal.pone.0181590.t006
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subgroup analysis on high-titer CMV-DNA patients demonstrated that the survival probability
of patients with ganciclovir treatment was higher than that of patients without ganciclovir
treatment (Fig 1b), but it was not statistically significant, which is possibly due to small sample
size. The CMV negative conversion rate after ganciclovir treatment was significantly lower in
the non-survivor group (Table 6), which suggests that the CMV treatment was not optimal in
the non-survivor group. Given that only 57.7% of the non-survivors had received ganciclovir
(Table 2), a delay in the detection of CMV infection in non-survivors is also possible. Addi-
tionally, because treatments of other concurrent infections are also important for survival of
our patients with autoimmune diseases, it is difficult to evaluate the survival benefits of ganci-
clovir with heterogeneity of concurrent infections. Prospective studies with larger populations
are necessary to evaluate whether anti-viral treatment reduces mortality in high-risk patients.
There are several limitations to our study. First, as it is a retrospective cohort study, there
could be selective bias in collecting relevant information from the electronic medical records.
Second, our study population might have been skewed toward those with poor outcomes
because CMV PCR tests were usually performed when the clinical course of the patient wors-
ened. These factors might have influenced the high mortality rate observed in CMV-DNA—
positive patients. Third, treatments for CMV disease were not controlled. Fourth, we were not
able to determine if the CMV infection detected in our patients was due to truly latent virus or
due to replicating but asymptomatic virus because we did not evaluate the CMV gene expres-
sion data such as the expression of CMV latent genes in the absence of CMV lytic genes. Lastly,
the stage of CMV infection (primary vs recurrent) was not evaluated.
In summary, the present study revealed a significant association between CMV-DNA copy
numbers, other bacterial and fungal infections, and mortality rates in autoimmune patients
with concurrent CMV infection. Therefore, we recommend evaluations for CMV end-organ
diseases such as CMV pneumonitis, serial follow-ups to monitor CMV-DNA copy numbers,
and surveillance for other bacterial and fungal infections in CMV PCR positive patients with
autoimmune diseases.
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